Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13% ± 1.21% in 4 mg group and –0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.
Abstract
Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13% ± 1.21% in 4 mg group and –0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.
참고문헌 (28)
- The Scandinavian Simvastatin Survival Study (4S)., "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease", Lancet, 344, pp.1383~1389 (1994)
- Sacks FM, "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators", N Engl J Med, 335, pp.1001~1009 (1996)
- Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group., "Prevention of cardiovas-cular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels", N Engl J Med, 339, pp.1349~1357 (1998)
- Heart Protection Study Collaborative Group., "MRC", BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, 2002, pp.360, 7~22
- Shepherd J, "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia:West of Scotland Coronary Prevention Study Group", N Engl J Med, 333, pp.1301~1307 (1995)
- Downs JR, "Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS", TexCAPS. Air Force, JAMA, pp.1998, 279[DOI]
- Shepherd J, "Pravastatin in elderly individuals at risk of vascular disease (PROSPER):a randomised controlled trial", Lancet, 360, pp.1623~1630 (2002)
- Cannon CP, "Intensive versus moderate lipid lowering with statins after acute coronary syndromes", N Engl J Med, 350, pp.1495~1504 (2004)
- Ridker PM, "C-reactive protein levels and outcomes after statin therapy", N Engl J Med, 352, pp.20~28 (2005)
- LaRosa JC, "Intensive lipid lowering with atorvastatin in patients with stable coronary disease", N Engl J Med, 352, pp.1425~1435 (2005)
- Nissen SE, "Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial", JAMA, 291, pp.1071~1080 (2004)
- Nissen SE, "Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease", N Engl J Med, 352, pp.29~38 (2005)
- Nissen SE, "Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial", JAMA, 295, pp.1556~1565 (2006)
- Lee SW, "Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients: the VENUS study", Circ J, 76, pp.2662~2672 (2012)
- Natsuaki M, "Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization: perspectives from the CREDO-Kyoto registry cohort-2", Circ J, 76, pp.1369~1379 (2012)
- Okada K, "Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: sub-analysis of the TWINS study", Circ J, 76, pp.1197~1202 (2012)
- Noji Y, "Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia", Atherosclerosis, 163, pp.157~164 (2002)
- ), "Am J Cardiol", 2011, 1530~1535
- Hong YJ, "Effect of pitavastatin treatment on changes of plaque volume and composition according to the reduction of high-sensitivity C-reactive protein levels", J Cardiol, 60, pp.277~282 (2012)
- Chen KY, "Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention", Circulation, 119, pp.3207~3214 (2009)
- Ridker PM, "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med, 359, pp.2195~2207 (2008)
- Sasaki J, "Statins: beneficial or adverse for glucose metabolism", J Atheroscler Thromb, 13, pp.123~129 (2006)
- Yamakawa T, "Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus", J Atheroscler Thromb, 15, pp.269~275 (2008)
- Saku K, "Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial", Circ J, 75, pp.1493~1505 (2011)
- Nakata M, "Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control", Diabetologia, 49, pp.1881~1892 (2006)
- Ishihara Y, "Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice", Atherosclerosis, 212, pp.131~138 (2010)
- Mita T, "Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia", J Diabetes Investig, 4, pp.297~303 (2013)
- Drew BG, "High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus", Circulation, 119, pp.2103~2111 (2009)